Has Elliot Michel received payments from drug or device companies?

Yes. Drug and device makers reported $360,444 in general payments to Elliot Michel across 2,091 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Elliot Michel did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Elliot Michel come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Elliot Michel

Neurology · Brackenridge, PANPI 1902807845

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $279,069 of the $360,444 with a category attached, or 77.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 22.6%. Reporting peaked in 2019 at $122,511 and has fallen 99.9% since, to $104 in 2024. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$360,444in general payments, 2019–2025

Across 2,091 payments — averaging $172.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$81K
Biogen$52K
AbbVie$47K
Avanir Pharmaceuticals, Inc.$32K
Mallinckrodt Hospital Products Inc.$30K
Lilly USA, LLC$22K
plus $96K from 54 others

$32,034in research payments, 2019–2025

Across 24 payments — averaging $1334.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Biogen$29K
Teva Pharmaceuticals USA, Inc.$3K

What the payments were for

Consulting fees$23,7897%
Speaking & faculty fees$279,06977%
Travel & lodging$12,3003%
Food & beverage$44,91712%
Education$3690%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	172	$81,307
Biogen	140	$51,940
AbbVie(2 entities)	267	$47,420
Avanir Pharmaceuticals, Inc.	88	$31,887
Mallinckrodt Hospital Products Inc.	66	$30,041
Lilly USA, LLC	122	$22,154
Mallinckrodt Enterprises LLC	26	$18,563
Novartis	126	$15,962
Biohaven Pharmaceuticals, Inc.	45	$14,597
Johnson & Johnson	60	$12,990
UCB, Inc.	92	$6,597
Acadia Pharmaceuticals Inc	67	$5,445
Biohaven Pharmaceutical Holding Company Ltd.	14	$2,871
EMD Serono, Inc.	67	$2,810
Teva Pharmaceuticals USA, Inc.	81	$1,777
Amgen(2 entities)	50	$1,401
Banner Life Sciences, LLC	20	$1,028
Genentech USA, Inc.	46	$1,020
Lundbeck LLC	40	$963
AstraZeneca(2 entities)	24	$948
Supernus Pharmaceuticals, Inc.	83	$703
Abbott	27	$591
Harmony Biosciences LLC	28	$555
Kyowa Kirin, Inc.	29	$554
SK Life Science, Inc.	28	$456
Jazz Pharmaceuticals Inc.	21	$445
Acorda Therapeutics, Inc	12	$433
Tanabe Pharma America, Inc.	13	$336
E.r. Squibb & Sons, L.L.C.	4	$329
Livanova USA, Inc.	12	$318
Bristol Myers Squibb	19	$308
MDD US Operations, LLC	21	$296
Neurelis, Inc.	12	$290
Amneal Pharmaceuticals LLC	12	$284
Eisai Inc.	9	$279
Neurocrine Biosciences, Inc.	9	$245
Upsher-smith Laboratories LLC	12	$233
Sunovion Pharmaceuticals Inc.	20	$230
Adamas Pharmaceuticals, Inc.	12	$225
Arbor Pharmaceuticals, Inc.	13	$221
Merck	11	$175
Vertical Pharmaceuticals, LLC	11	$143
Impel Pharmaceuticals Inc.	2	$140
Argenx US, Inc.	7	$139
Bausch Health US, LLC	6	$114
Pfizer	6	$100
Currax Pharmaceuticals LLC	5	$73
Zyla Life Sciences, Inc.	4	$53
Assertio Therapeutics, Inc.	3	$52
Promius Pharma LLC	3	$46
GE HealthCare	4	$41
Sanofi-aventis U.S. LLC	2	$37
Alnylam Pharmaceuticals Inc.	2	$36
Otsuka America Pharmaceutical, Inc.	2	$35
Almatica Pharma LLC	2	$32
Collegium Pharmaceutical, Inc.	2	$31
Preventice Services, LLC	2	$31
Nevro Corp.	1	$29
Greenwich Biosciences, Inc.	2	$28
Sumitomo Pharma America, Inc.	2	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ACTHAR$47,168
AUBAGIO$47,039
UBRELVY$43,346
NUEDEXTA$30,754
TYSABRI$27,675
NURTEC ODT$16,724
LEMTRADA$16,146
Vumerity$16,105
EMGALITY$12,830
Ponvory$7,635
GILENYA$7,259
MAYZENT$5,955
NUPLAZID$4,434
Briviact$3,750
TECFIDERA$1,107
AVONEX$1,107
PLEGRIDY$1,107
AIMOVIG$566
DISEASE STATE$464
Mavenclad$369

How this compares

$360,444 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Divalproex Sodium ErDivalproex Sodium	12	$2,325

Paid to pharmacies, not to this prescriber.

Other neurology in Brackenridge

Daniel KremensPhiladelphia$1.8M
Thomas LeistPhiladelphia$1.4M
Jill Giordano FarmerPhiladelphia$1.2M
Ravi DukkipatiYork$936K
Brad KleinAbington$927K
Stephanie Nahas-GeigerPhiladelphia$786K
John KhouryAbington$686K
Amit Bar-OrPhiladelphia$596K
Behrang SaminejadAllentown$594K
Anoopum GuptaPittsburgh$592K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →